COVID-19 Vaccine, Adjuvanted (NUVAXOVID)
COVID-19 Vaccine, Adjuvanted is an FDA-licensed reference biologic from Novavax, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2025
Reference approved
Reference product
NUVAXOVID COVID-19 Vaccine, Adjuvanted
Novavax, Inc.
- Approved
- May 16, 2025
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for COVID-19 Vaccine, Adjuvanted, in chronological order.
Reference approval
Approval date of the reference COVID-19 Vaccine, Adjuvanted product.
1 yr 1 mo ago
Frequently asked questions
Are there biosimilars approved for COVID-19 Vaccine, Adjuvanted (NUVAXOVID)?
No 351(k) biosimilars or interchangeable biosimilars referencing COVID-19 Vaccine, Adjuvanted are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.